Journal of Gerontological Nursing

Product News Free

Product News

Emergency Response System App

FallCall Solutions launched its second product, FallCall Lite, a personal emergency response system application built exclusively for Apple watch® and iPhone®. FallCall Lite's unique features include voice activation using Siri®, Apple watch battery power monitoring by caregivers, and a fully integrated subscription-based central monitoring service. The central monitoring service, staffed by trained emergency medical dispatchers, provides real-time emergency event updates through electronic messaging to up to five caregivers on their iPhone or Apple watch simultaneously and is available 24/7. FallCall Lite is free to download and use. Optional central monitoring is available for an additional fee per month.

Source.“FallCall: A New Generation of Personal Emergency Assistant App Comes to Apple Watch® and iPhone®” (2018, August 2). Retrieved September 25, 2018, from https://prn.to/2DqZuYI.

U.S. Food and Drug Administration Approves First Nonpharmacological Prescription Treatment for Alzheimer's Disease

Dthera Sciences announced that the U.S. Food and Drug Administration granted breakthrough device designation to the company's development-stage product, DTHR-ALZ.

DTHR-ALZ, if granted approval, will be the first nonpharmacological prescription treatment for symptoms of Alzheimer's disease (AD). DTHR-ALZ is intended to be a prescription digital therapeutic that will deliver reminiscence therapy to patients with AD. The device will use artificial intelligence to automatically optimize the therapy based on various forms of biofeedback from the patient. According to the Alzheimer's Association, reminiscence therapy is an evidence-based psychosocial intervention that has been shown in clinical trials to improve symptoms of the disorder, but adoption of the therapy has been limited because of the investment of caregiver time and resources. DTHR-ALZ, however, will provide reminiscence therapy with more frequency, consistency, and personalization while requiring minimal time and resources.

Source.“Dthera Sciences Receives FDA Breakthrough Device Designation for Alzheimer's Focused Development-Stage Product ‘DTHR-ALZ’” (2018, August 23). Retrieved September 25, 2018, from https://prn.to/2IdFVlE.

Authors

10.3928/00989134-20181010-02

Sign up to receive

Journal E-contents